# PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

> **NCT00679835** · PHASE1 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 24 (actual)

## Conditions studied

- Gram Positive Infection
- Concurrent Antibiotic Treatment

## Interventions

- **DRUG:** daptomycin

## Key facts

- **NCT ID:** NCT00679835
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-03
- **Primary completion:** 2008-11-20
- **Final completion:** 2008-11-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679835, "PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00679835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*